雪榕生物(300511) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 reached ¥675,808,928.45, representing a 35.03% increase year-over-year[6] - Net profit attributable to shareholders was ¥107,044,675.06, a significant increase of 339.54% compared to the same period last year[6] - The basic earnings per share rose to ¥0.21, reflecting a 310.00% increase year-over-year[6] - Total operating revenue for the current period reached ¥1,649,344,357.67, an increase of 15.4% compared to ¥1,429,298,969.19 in the previous period[24] - The net profit for the current period was a loss of ¥7,016,834.22, an improvement from a loss of ¥143,764,632.81 in the previous period[25] - Total comprehensive income for the current period was a loss of ¥8,314,113.31, compared to a loss of ¥155,792,313.28 in the previous period, indicating a significant reduction in losses[25] Cash Flow - Operating cash flow net amount for the year-to-date was ¥176,348,880.42, up 148.46% from the previous year[12] - Cash flow from operating activities generated a net amount of ¥176,348,880.42, compared to ¥70,975,793.40 in the previous period, indicating a positive trend[26] - The net cash flow from financing activities surged to ¥313,830,951.19, a 3620.84% increase, attributed to funds raised from issuing shares[12] - The total cash and cash equivalents at the end of the period reached CNY 460,946,877.58, up from CNY 310,782,975.99[27] - The company experienced a net increase in cash and cash equivalents of CNY 121,566,461.70, contrasting with a decrease of CNY 449,091,333.34 in the prior period[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,590,867,399.61, an increase of 5.78% from the end of the previous year[6] - The company's total liabilities were RMB 2.557 billion, a decrease from RMB 2.686 billion at the beginning of the year[22] - The company's current assets totaled RMB 1.243 billion, up from RMB 874.94 million at the beginning of the year[21] - The company's inventory increased to RMB 464.92 million from RMB 384.08 million at the beginning of the year[21] Shareholder Information - The total number of common shareholders at the end of the reporting period is 33,282[14] - The largest shareholder, Yang Yongping, holds 21.39% of shares, totaling 107,606,850 shares[14] - The company has a diverse shareholder base, including various investment funds and private equity firms[15] - The company is actively managing its shareholder structure to comply with regulatory requirements and enhance shareholder value[16] Investment and Development - The company reported a 927.82% increase in investment income, amounting to ¥14,225,226.09, primarily due to gains from the transfer of subsidiary equity[11] - Research and development expenses decreased by 54.91% to ¥5,607,961.11, mainly due to the shutdown of the Shanghai base[11] - The company acquired a 5% stake in Dafa Xuerong Biotechnology Co., Ltd. for RMB 1.997 million, increasing its total ownership to 69%[18] - The company decided to postpone the Anhui Xuerong Pleurotus eryngii project completion date to August 30, 2024, due to intense market competition and rising raw material costs[18] Regulatory and Compliance - The company has received approval from the China Securities Regulatory Commission for a stock issuance to specific targets, allowing for the issuance of 65,676,567 new shares[17] - The new shares from the specific target issuance were listed on the Shenzhen Stock Exchange on March 21, 2022[17] - The company is subject to lock-up regulations for executives, with Yang Yongping's shares locked for the duration of her tenure[16] Other Financial Metrics - The company reported a short-term loan of RMB 732.68 million, down from RMB 777.49 million at the beginning of the year[22] - The company paid CNY 867,557,375.03 in cash for debt repayment, up from CNY 626,772,839.20[27] - The company reported a foreign exchange impact of CNY 6,657.96 on cash and cash equivalents, compared to a negative impact of CNY -3,616,779.83 in the previous period[27] - The company did not have its third-quarter report audited[28]